The results of the StemEx study are expected during the
second half of 2012

JERUSALEM--(BUSINESS WIRE)--Feb 13, 2012 - Gamida Cell announced
today that the Gamida Cell-Teva Joint Venture (JV), equally held by
Gamida Cell and Teva Pharmaceutical Industries, has enrolled the
last of 100 patients in the international, multi-center, pivotal
registration, Phase III clinical trial of StemEx, a cell therapy
product in development as an alternative therapeutic treatment for
adolescents and adults, with blood cancers such as leukemia and
lymphoma, who cannot find a family related, matched bone marrow
donor.

StemEx is a graft of an expanded population of stem/progenitor
cells, derived from part of a single unit of umbilical cord blood
and transplanted by IV administration along with the remaining,
non-manipulated cells from the same unit.

Dr. Yael Margolin, president and chief executive officer of
Gamida Cell, said, "The JV is planning to announce the safety and
efficacy results of the Phase III StemEx trial in 2012 and to
launch the product into the market in 2013. It is our hope that
StemEx will provide the answer for the thousands of leukemia and
lymphoma patients unable to find a matched, related bone marrow
donor.”

Dr. Margolin continued, “StemEx may be the first
allogeneic cell therapy to be brought to market. This is a source
of pride for Gamida Cell, as it further confirms the company's
leadership as a pioneer in cell therapy. In addition to StemEx,
Gamida Cell is developing a diverse pipeline of products for the
treatment of cancer, hematological diseases such as sickle cell
disease and thalassemia, as well as autoimmune and metabolic
diseases and conditions helped by regenerative medicine.”

About Gamida Cell

Gamida Cell is a world leader in stem cell population expansion
technologies and stem cell therapy products for transplantation and
regenerative medicine. The company's pipeline of stem cell therapy
products are in development to treat a wide range of conditions
including blood cancers such as leukemia and lymphoma, solid
tumors, non-malignant hematological diseases such as
hemoglobinopathies, acute radiation syndrome, autoimmune diseases
and metabolic diseases as well as conditions that can be helped by
regenerative medicine. Gamida Cell's therapeutic candidates contain
populations of adult stem cells, selected from non-controversial
sources such as umbilical cord blood, which are expanded in
culture. Gamida Cell was successful in translating these
proprietary expansion technologies into robust and validated
manufacturing processes under GMP. Gamida Cell's current
shareholders include: Elbit Imaging, Clal Biotechnology Industries,
Israel Healthcare Venture, Teva Pharmaceutical Industries, Amgen,
Denali Ventures and Auriga Ventures. For more information, please
visit:
www.gamida-cell.com.